Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy
By M. Shahnawaz, Abhisek Mukherjee, S. Pritzkow, Nicolas Mendez, Prakruti Rabadia, Xiangan Liu, Bo Hu, A. Schmeichel, W. Singer, Gang Wu and 5 more. Nature, 2020
677 citations recorded by the source corpus.
Synucleinopathies are neurodegenerative diseases that are associated with the misfolding and aggregation of α-synuclein, including Parkinson’s disease, dementia with Lewy bodies and multiple system atrophy1. Clinically, it is challenging to differentiate Parkinson’s disease and multiple system atrophy, especially at the early stages of disease2. Aggregates of α-synuclein in distinct synucleinopathies have been proposed to represent different conformational strains of α-synuclein that can self-propagate and spread from cell to cell3–6. Protein misfolding cyclic amplification (PMCA) is a technique that has previously been used to detect α-synuclein aggregates in samples of cerebrospinal fluid with high sensitivity and specificity7,8. Here we show that the α-synuclein-PMCA assay can discriminate between samples of cerebrospinal fluid from patients diagnosed with Parkinson’s disease and samples from patients with multiple system atrophy, with an overall sensitivity of 95.4%. We used a combination of biochemical, biophysical and biological methods to analyse the product of α-synuclein-PMCA, and found that the characteristics of the α-synuclein aggregates in the cerebrospinal fluid could be used to readily distinguish between Parkinson’s disease and multiple system atrophy. We also found that the properties of aggregates that were amplified from the cerebrospinal fluid were similar to those of aggregates that were amplified from the brain. These findings suggest that α-synuclein aggregates that are associated with Parkinson’s disease and multiple system atrophy correspond to different conformational strains of α-synuclein, which can be amplified and detected by α-synuclein-PMCA. Our results may help to improve our understanding of the mechanism of α-synuclein misfolding and the structures of the aggregates that are implicated in different synucleinopathies, and may also enable the development of a biochemical assay to discriminate between Parkinson’s disease and multiple system atrophy. Protein misfolding cyclic amplification (PMCA) technology can discriminate between patients with Parkinson’s disease and patients with multiple system atrophy on the basis of the characteristics of the α-synuclein aggregates in the cerebrospinal fluid.
Subfields: Neurology
View Paper: https://www.semanticscholar.org/paper/e60cc8c210165d74e878674a266d9b719a2fdedb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
Citations in the corpus
- Aging and aging-related diseases: from molecular mechanisms to interventions and treatments (2022, background): “Chronic obstructive pulmonary disease (COPD) Senolytics is an antiaging treatment that has attracted much attention recently, and dasatinib and quercetin have been used in clinical trials for idiopathic pulmonary fibrosis.625 However, to date, no convincing clinical trials have confirmed that senoly”
- Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction (2023, background): “A recent study investigating MSA models with cognitive impairment demonstrated that α-syn was first expressed in oligodendrocytes but then accumulated in the cytoplasm of excitatory hippocampal neurons and their presynaptic nerve terminals [109].”